Evidence map›Paper›PMID 30669305›Full record

ArticleHealthcare (Basel, Switzerland)2019

Use of a Cross-Sectional Survey in the Adult Population to Characterize Persons at High-Risk for Chronic Obstructive Pulmonary Disease.

Roy A Pleasants, Khosrow Heidari, Jill Ohar, James F Donohue, Njira Lugogo, Chelsea L Richard, Sarojina Kanotra, David M Mannino, Monica Kraft, Winston Liao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. The COPD Foundation on Its Twentieth Anniversary.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Roy A PleasantsDivision of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. pleas005@email.unc.edu.
Khosrow HeidariSouth Carolina Department of Health and Environmental Control, Columbia, SC 29201, USA. heidarik@dhec.sc.gov.
Jill OharPulmonary, Critical Care, Allergy, Immunologic Diseases Section, Wake Forest University, Winston-Salem, NC 27109, USA. johar@wakehealth.edu.ORCID 0000-0002-2757-6806
James F DonohueDivision of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. james_donohue@med.unc.edu.
Njira LugogoDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI 48109, USA. nlugogo@med.umich.edu.
Chelsea L RichardSouth Carolina Department of Health and Environmental Control, Columbia, SC 29201, USA. richarcl@dhec.sc.gov.ORCID 0000-0002-0517-0223
Sarojina KanotraKentucky Department for Public Health, State Public Health Agency, Frankfort, KY 40621, USA. sarojini.kanotra@ky.gov.
David M ManninoDepartment of Medicine, University of Kentucky, Lexington, KY 40506, USA. dmmann2@email.uky.edu.
Monica KraftDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85721, USA. mkraft@deptofmed.arizona.edu.
Winston LiaoIndependent Researcher, Chapel Hill, NC 27599, USA. winston.liao1@gmail.com.
Charlie StrangeDivision of Pulmonary, Critical Care and Sleep Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. strangec@musc.edu.
South Carolina Department of Health and Environmental Control · USUniversity of North Carolina at Chapel Hill · USKentucky Department for Public Health · USMedical University of South Carolina · USUniversity of Arizona · USUniversity of Kentucky · USUniversity of Michigan · USWake Forest University · US

Funding

SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI George S Watts · 1994 to 2026
$36.7M
GlaxoSmithKline 0001GlaxoSmithKline 12-123-34GlaxoSmithKline USA 0001NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Rationale/Objective: The Behavioral Risk Factor Surveillance System (BRFSS) health survey has been used to describe the epidemiology of chronic obstructive pulmonary disease (COPD) in the US. Through addressing respiratory symptoms and tobacco use, it could also be used to characterize COPD risk.

methodsFour US states added questions to the 2015 BRFSS regarding productive cough, shortness of breath, dyspnea on exertion, and tobacco duration. We determined COPD risk categories: provider-diagnosed COPD as self-report, high-risk for COPD as ≥10 years tobacco smoking and at least one significant respiratory symptom, and low risk was neither diagnosed COPD nor high risk. Disease burden was defined by respiratory symptoms and health impairments. Data were analyzed using multiple logistic regression models with age as a covariate.

resultsAmong 35,722 adults ≥18 years, the overall prevalence of COPD and high-risk for COPD were 6.6% and 5.1%. Differences among COPD risk groups were evident based on gender, race, age, geography, tobacco use, health impairments, and respiratory symptoms. Risk for disease was seen early where 3.75% of 25⁻34 years-old met high-risk criteria. Longer tobacco duration was associated with an increased prevalence of COPD, particularly >20 years. Seventy-nine percent of persons ≥45 years-old with frequent shortness of breath (SOB) reported having or being at risk of COPD, reflecting disease burden.

conclusionThese data, representing nearly 18% of US adults, indicates those at high risk for COPD share many, but not all of the characteristics of persons diagnosed with the disease and demonstrates the value of the BRFSS as a tool to define lung health at a population level.

Indexed as

body mass indexcomorbiditiesdyspnea on exertionhealth impairmentproductive coughshortness of breathtobacco smokingundiagnosed COPD

Identifiers

PMID30669305
PMCPMC6473439
OpenAlexW2909637271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.